Suppr超能文献

肠道微生物群与糖尿病肾病的研究进展

Research progress of gut microbiome and diabetic nephropathy.

作者信息

Chu Chenling, Behera Tapas Ranjan, Huang Ying, Qiu Wenhui, Chen Jiayi, Shen Quanquan

机构信息

Department of Clinical Medicine, Hangzhou Normal University, Hangzhou, China.

Department of Cancer Biology, Cleveland Clinic, Cleveland, OH, United States.

出版信息

Front Med (Lausanne). 2024 Dec 13;11:1490314. doi: 10.3389/fmed.2024.1490314. eCollection 2024.

Abstract

Diabetic nephropathy is an important complication of diabetic microvascular injury, and it is also an important cause of end-stage renal disease. Its high prevalence and disability rate significantly impacts patients' quality of life while imposing substantial social and economic burdens. Gut microbiota affects host metabolism, multiple organ functions, and regulates host health throughout the life cycle. With the rapid development of technology, researchers have found that gut microbiota is closely related to the progression of diabetic kidney disease. This review explores the role of gut microbiome in diabetic nephropathy summarizing proposed mechanisms of progression and focusing on microbial metabolites, intestinal barrier disruption, inflammation, filtration barrier damage and renal fibrosis. This review also examines the mechanism and limitations of current treatments, including drugs, fecal microbiota transplantation, and lifestyle changes, offering new perspectives on prevention and treatment.

摘要

糖尿病肾病是糖尿病微血管损伤的重要并发症,也是终末期肾病的重要原因。其高患病率和致残率显著影响患者的生活质量,同时带来巨大的社会和经济负担。肠道微生物群影响宿主代谢、多器官功能,并在整个生命周期中调节宿主健康。随着技术的快速发展,研究人员发现肠道微生物群与糖尿病肾病的进展密切相关。本综述探讨了肠道微生物群在糖尿病肾病中的作用,总结了其进展的潜在机制,并重点关注微生物代谢产物、肠屏障破坏、炎症、滤过屏障损伤和肾纤维化。本综述还研究了当前治疗方法(包括药物、粪便微生物群移植和生活方式改变)的机制和局限性,为预防和治疗提供了新的视角。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e90/11671260/42eeb0e174a3/fmed-11-1490314-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验